Abstract 2299P
Background
Mebendazole (Mbz), a well-known anthelminthic drug, has been demonstrated to have anti-cancer properties in tumor models and patients. The therapeutic effect of Mbz was suggested to be due to microtubule inhibition, but more recently we reported that Mbz switches macrophages from the M2 to the tumor suppressive M1 phenotype. The aims of this study were to further investigate in tumor models the cytotoxic and immunomodulatory effects of Mbz alone, in combination with cytotoxic drugs and PD-1 antibody.
Methods
Tumor samples from patients with solid or hematological malignancies undergoing diagnostic or therapeutic procedures were obtained in accordance with ethical permission. The samples were then prepared to isolated tumor cells for ex vivo testing. Ex vivo activity of Mbz alone and in combination with standard cytotoxic drugs was assessed using the fluorometric microculture cytotoxic assay. Survival index and synergy scores were calculated using GraphPad and SynergyFinder. In vivo antitumor activity of Mbz, irinotecan, a PD-1 inhibitor and their combinations were examined in a murine BALB/c model with inoculated syngeneic colon cancer cells (CT26). Tumor growth was measured by caliper and tumors were retrieved and assessed by flow cytometry for immune cell infiltration.
Results
Mbz alone showed some modest cytotoxic activity against patient tumor cells ex vivo, with hematological tumor cells being slightly more sensitive. The cytotoxic effect of Mbz was generally additive to that of other drugs but synergistic when combined with irinotecan. In the murine model, Mbz, irinotecan and the PD-1 antibody alone inhibited tumor growth. Combined with irinotecan Mbz had an additive effect, but was synergistic when combined with the PD-1 antibody. In line with the latter observation, flow cytometry showed an increase of M1 macrophages and decrease of M2 macrophages in tumors from animals treated with the combination.
Conclusions
Mbz show promising features making it suitable for repositioning into an anti-cancer drug, most notably as a modulator of the macrophage phenotype that may enhance and the effect of check-point inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sharmineh Mansoori.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08